PharmaTimes - June 2018

The 2018 Communications Team of the Year awards are now open for entry, so on p32 we thought we’d ask some top pharma communicators what trends and issues comms teams need to be paying attention to right now. (And given that they’re all on the CTOY steering committee, those of you thinking of entering might want to pay attention!)

Speaking of competitions, the past month has seen both of our Clinical Researcher awards revealing their winners, and we have full coverage on p36-39.

Elsewhere in the mag we take a look at the hurdles biosimilars still need to overcome to reach their full potential in the market (p30), the current state of gene therapy (p22), GSK’s financial woes (p20) and what could be the first marketed treatment for traumatic brain injury (p28).

June 2018 - magazine highlights

Patient Files: Familial Chylomicronaemia Syndrome

Dr Karishma Patel talks to PharmaTimes about the challenge...

Together as one

We caught up with IQVIA’s SVP global technology solutions,...

Company focus: Vasopharm

CEO Christian Wandersee explains the hurdles and hopes whe...

Is trouble on the horizon for GSK?

Ana Nicholls asks whether GSK’s revenue drop is a short-te...

The ultimate cure?

Gene therapy still needs to overcome some major hurdles to...

How can pharma support NHS transformation?

Steve How, Paul Midgley and Oli Hudson of the Wilmington C...

The biosimilars era

Biosimilars may have proven their worth, but how can adopt...

On the comms radar

Pharma comms is one of the most dynamic  sectors of the in...